hotspot -WSS

hotspot

author：fashion 2025-10-02 21:06:21 - browse：9

David Sabatini at home — David Sabatini posed at his home in Cambridge in 2022. Craig F. Walker/Boston Globe

Former MIT and Whitehead Institute star biologist David Sabatini, who lost his lofty positions after being accused of violating sexual harassment policies in 2021, is rejoining the Boston scientific community as head of a research group at a new laboratory under the umbrella of a Czech-based scientific institute.

Sabatini, who has denied harassing anyone and filed litigation over the claims, has been working since last October in a senior research position at the Institute of Organic Chemistry and Biochemistry, in the Czech Republic capital of Prague, investigating scientific questions in the areas of cell growth and metabolism, similar to his past research at Whitehead.

The Czech institute, known as IOCB Prague, is realizing a long-held ambition to expand into the Boston biotech hub, confirmed the institute’s director, Jan Konvalinka.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： The battle over 'scope creep' and who gets to be called 'doctor'

WSS

Will the FTC rein in IQVIA's health data empire?

What causes rare myocarditis in young men after Covid vaccines?

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

A new crop of companies is reshaping the health data economy

The haunting brain science of long Covid

FDA panel to weigh approval of NurOwn, controversial ALS drug

hotspot

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

explore

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Lasker Awards 2023: Winners in biomedical research

Cancer drug shortages should be causing more outrage

Biotech stock slump in 2023: awaiting the turnaround

Alkermes shareholders re

How AI helped researchers track recovery from depression

Jerome Adams on the need for new antivirals for Covid

Senate panel puts off hardest PBM reforms for another day

Sports medicine is finally prioritizing gender equality

New Alzheimer's drugs heat up race for early detection blood tests

hotspot

Microbiome research is starting to find links to chronic diseases

Emergency workers more likely to restrain Black patients: study

How doctors’ personal politics affect patients

A new crop of companies is reshaping the health data economy

FDA panel to weigh approval of NurOwn, controversial ALS drug

It's been 20 years since Dolly the sheep. Where's my clone?

entertainment

focus

focus

leisure time